Search

Macular atrophy with aflibercept

The authors of this paper set out to investigate the prevalence of macular atrophy in treatment-naive patients with neovascular AMD undergoing aflibercept monotherapy (three monthly loading injections followed by subsequent treatment every two months). Case notes over a three year...

Atrophy and anti-VEGF

The aim of this study was to investigate treatment factors, along with ocular and systemic factors for their association with macular atrophy (MA) incidence in eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF aflibercept or ranibizumab according to...

Macular atrophy and choriocapillaris nonperfusion

This Japanese study compared the choriocapillaris (CC) nonperfusion area as measured on OCTA with areas of macular atrophy (MA) measured by fundus autofluoresence (FAF). A total of 44 eyes were assessed (31 were treated with anti-VEGF alone and 13 had...

OCTA in geographic atrophy

In this article the authors aim to give an overview of the current literature concerning the application of OCT-A in geographic atrophy (GA). GA is a disease characterised by loss of outer retinal layers including photoreceptors, degeneration of the retinal...

Role of fundus autofluorescence patterns and baseline atrophy area on geographic atrophy progression

Central geographic atrophy (GA) is one of the morphological sub types of late-stage macular degeneration. The natural course of the disease is characterised by expanding areas of macular atrophy, which cause absolute scotoma. Fundus autofluorescence (FAF) is derived from lipofuscin...

RPE atrophy onset in treated nAMD

In this study the authors aim to evaluate the role of various factors for the development of retinal pigment epithelium (RPE) atrophy over a period of five years in patients with nAMD. Fifty-two newly diagnosed nAMD patients with complete absence...

Progression of macular atrophy in Stargardt disease

The authors present a study of a cohort of patients with genetically proven ABCA4 gene mutation related Stargardt disease. They aimed to quantify the effect of lesion location and topography on disease progression using fundus autofluorescence imaging. One hundred and...

Detection of SO tendon abnormality versus atrophy

This study aimed to evaluate patterns of binocular misalignment in primary gaze, lateral and vertical gaze, and head tilt in patients showing head-tilt dependent hypertropia associated with discontinued superior oblique (SO) tendon but without SO muscle atrophy, versus patients with...

Chorioretinal atrophy in punctate inner choroidopathy / multifocal choroiditis

This study reported the five-year outcomes of chorioretinal atrophy (CRA) progression in patients with punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) in 45 eyes of 36 patients. The mean age of the cohort of patients was 37 ±13.37 years...

Could idebenone by the solution for treating dominant optic atrophy?

Dominant optic atrophy (DOA) is a disease of the retinal ganglion cells, with no current treatment options. In most cases, DOA is caused by a mutation in the OPA1 gene. The aim of this study was to evaluate the effect...

Progression of macular atrophy on long-term anti-VEGF therapy for AMD

This retrospective study evaluated the progression of macular atrophy in 53 eyes of 53 patients receiving AntiVEGF Therapy for age-related macular degeneration (nAMD), for at least six years. None of the patients had any macular atrophy (MA) at presentation. MA...